Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Esophageal Cancer
Interventions
DRUG

S1

PO, 40\~60mg,BID(d1-14,d22-35,two cycles)

DRUG

Iparomlimab

IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)

RADIATION

Radiation

Concurrent Radiation, 1.8Gy/f, 28f;

Trial Locations (1)

Unknown

RECRUITING

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER